Literature DB >> 22890772

Risk factors for infection or colonization with CTX-M extended-spectrum-β-lactamase-positive Escherichia coli.

Jennifer H Han1, Kei Kasahara, Paul H Edelstein, Warren B Bilker, Ebbing Lautenbach.   

Abstract

There has been a significant increase in the prevalence of Enterobacteriaceae that produce CTX-M-type extended-spectrum β-lactamases. The objective of this study was to evaluate risk factors for infection or colonization with CTX-M-positive Escherichia coli. A case-control study was conducted within a university system from 1 January 2007 to 31 December 2008. All patients with clinical cultures with E. coli demonstrating resistance to extended-spectrum cephalosporins were included. Case patients were designated as those with cultures positive for CTX-M-positive E. coli, and control patients were designated as those with non-CTX-M-producing E. coli. Multivariable logistic regression analyses were performed to evaluate risk factors for CTX-M-positive isolates. A total of 83 (56.8%) of a total of 146 patients had cultures with CTX-M-positive E. coli. On multivariable analyses, there was a significant association between infection or colonization with CTX-M-type β-lactamase-positive E. coli and receipt of piperacillin-tazobactam in the 30 days prior to the culture date (odds ratio [OR], 7.36; 95% confidence interval [CI], 1.61 to 33.8; P = 0.01) and a urinary culture source (OR, 0.36; 95% CI, 0.17 to 0.77; P = 0.008). The rates of resistance to fluoroquinolones were significantly higher in isolates from case patients than in isolates from control patients (90.4 and 50.8%, respectively; P < 0.001). We found that nonurinary sources of clinical cultures and the recent use of piperacillin-tazobactam conferred an increased risk of colonization or infection with CTX-M-positive E. coli. Future studies will need to focus on outcomes associated with infections due to CTX-M-positive E. coli, as well as infection control strategies to limit the spread of these increasingly common organisms.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22890772      PMCID: PMC3486585          DOI: 10.1128/AAC.01136-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  43 in total

1.  CTX-M beta-lactamase-producing Escherichia coli in French hospitals: prevalence, molecular epidemiology, and risk factors.

Authors:  Jean-Philippe Lavigne; Hélène Marchandin; Julien Delmas; Jérôme Moreau; Nicole Bouziges; Evelyne Lecaillon; Laurent Cavalie; Hélène Jean-Pierre; Richard Bonnet; Albert Sotto
Journal:  J Clin Microbiol       Date:  2006-11-15       Impact factor: 5.948

2.  Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis.

Authors:  Mitchell J Schwaber; Yehuda Carmeli
Journal:  J Antimicrob Chemother       Date:  2007-09-11       Impact factor: 5.790

3.  Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.

Authors:  Jesús Rodríguez-Baño; Juan C Alcalá; Jose M Cisneros; Fabio Grill; Antonio Oliver; Juan P Horcajada; Teresa Tórtola; Beatriz Mirelis; Gemma Navarro; María Cuenca; María Esteve; Carmen Peña; Ana C Llanos; Rafael Cantón; Alvaro Pascual
Journal:  Arch Intern Med       Date:  2008-09-22

4.  Epidemiology of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp.: a nested case-control study from a tertiary hospital in London.

Authors:  I Skippen; M Shemko; J Turton; M E Kaufmann; C Palmer; N Shetty
Journal:  J Hosp Infect       Date:  2006-07-21       Impact factor: 3.926

5.  Cephalosporin and fluoroquinolone combinations are highly associated with CTX-M β-lactamase-producing Escherichia coli: a case-control study in a French teaching hospital.

Authors:  P Cassier; S Lallechère; S Aho; K Astruc; C Neuwirth; L Piroth; P Chavanet
Journal:  Clin Microbiol Infect       Date:  2011-04-12       Impact factor: 8.067

6.  Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens.

Authors:  H Knothe; P Shah; V Krcmery; M Antal; S Mitsuhashi
Journal:  Infection       Date:  1983 Nov-Dec       Impact factor: 3.553

7.  Clinico-epidemiological features of infections caused by CTX-M type extended spectrum beta lactamase-producing Escherichia coli in hospitalised patients.

Authors:  Ronan McMullan; Anne C Loughrey; Mark McCalmont; Paul J Rooney
Journal:  J Infect       Date:  2006-02-14       Impact factor: 6.072

8.  Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK.

Authors:  N Woodford; M E Ward; M E Kaufmann; J Turton; E J Fagan; D James; A P Johnson; R Pike; M Warner; T Cheasty; A Pearson; S Harry; J B Leach; A Loughrey; J A Lowes; R E Warren; D M Livermore
Journal:  J Antimicrob Chemother       Date:  2004-09-03       Impact factor: 5.790

9.  Population-based laboratory surveillance for Escherichia coli-producing extended-spectrum beta-lactamases: importance of community isolates with blaCTX-M genes.

Authors:  Johann D D Pitout; Nancy D Hanson; Deirdre L Church; Kevin B Laupland
Journal:  Clin Infect Dis       Date:  2004-05-25       Impact factor: 9.079

10.  Molecular epidemiology of CTX-M-producing Escherichia coli isolates at a tertiary medical center in western Pennsylvania.

Authors:  Hanna E Sidjabat; David L Paterson; Jennifer M Adams-Haduch; Lindsay Ewan; Anthony W Pasculle; Carlene A Muto; Guo-Bao Tian; Yohei Doi
Journal:  Antimicrob Agents Chemother       Date:  2009-08-17       Impact factor: 5.191

View more
  6 in total

Review 1.  Clinical management of infections caused by multidrug-resistant Enterobacteriaceae.

Authors:  Mercedes Delgado-Valverde; Jesús Sojo-Dorado; Alvaro Pascual; Jesús Rodríguez-Baño
Journal:  Ther Adv Infect Dis       Date:  2013-04

2.  Intestinal decontamination of multidrug-resistant Klebsiella pneumoniae after recurrent infections in an immunocompromised host.

Authors:  Matthew P Kronman; Danielle M Zerr; Xuan Qin; Janet Englund; Cathy Cornell; Jean E Sanders; Jeffrey Myers; Jaipreet Rayar; Jessica E Berry; Amanda L Adler; Scott J Weissman
Journal:  Diagn Microbiol Infect Dis       Date:  2014-06-21       Impact factor: 2.803

3.  Comparative Effectiveness of Ceftriaxone plus Metronidazole versus Anti-Pseudomonal Antibiotics for Perforated Appendicitis in Children.

Authors:  Rana F Hamdy; Lori K Handy; Evangelos Spyridakis; Daniele Dona; Matthew Bryan; Joy L Collins; Jeffrey S Gerber
Journal:  Surg Infect (Larchmt)       Date:  2019-03-15       Impact factor: 2.150

Review 4.  A call to action for antimicrobial stewardship in the emergency department: approaches and strategies.

Authors:  Larissa May; Sara Cosgrove; Michelle L'Archeveque; David A Talan; Perry Payne; Jeanne Jordan; Richard E Rothman
Journal:  Ann Emerg Med       Date:  2012-11-02       Impact factor: 5.721

5.  Risk factors associated with the community-acquired colonization of extended-spectrum beta-lactamase (ESBL) positive Escherichia Coli. an exploratory case-control study.

Authors:  Rasmus Leistner; Elisabeth Meyer; Petra Gastmeier; Yvonne Pfeifer; Christoph Eller; Petra Dem; Frank Schwab
Journal:  PLoS One       Date:  2013-09-11       Impact factor: 3.240

Review 6.  Meta-analysis of proportion estimates of Extended-Spectrum-Beta-Lactamase-producing Enterobacteriaceae in East Africa hospitals.

Authors:  Tolbert Sonda; Happiness Kumburu; Marco van Zwetselaar; Michael Alifrangis; Ole Lund; Gibson Kibiki; Frank M Aarestrup
Journal:  Antimicrob Resist Infect Control       Date:  2016-05-14       Impact factor: 4.887

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.